{"product_id":"pharvaris-business-model-canvas","title":"Pharvaris Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: Strategic blueprint for a rare-disease biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Pharvaris’s business model with our Business Model Canvas, showing how the company creates value, scales partnerships and captures revenue. This concise analysis highlights customer segments, key activities and cost drivers. Purchase the complete, editable Word\/Excel canvas to benchmark strategy and inform investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs for global clinical trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnering with experienced CROs enables efficient execution of multi-country HAE studies, vital for a rare disease with prevalence near 1 in 50,000. CROs provide site management, electronic data capture and regulatory coordination across sites. They reduce operational risk and compress timelines. This allows Pharvaris to focus resources on science and strategic development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMOs for GMP drug supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCMOs scale Pharvaris oral small-molecule production under GMP, ensuring batch quality, stability and timely supply for trials and launch; tech-transfer and validation are co-managed with internal teams to de-risk commercialization. This enables reliable on-demand and prophylactic availability, with many CMOs able to scale to hundreds of kilograms per batch and the pharma CMO market \u0026gt;$80B in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOLs and academic centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKOLs in allergy\/immunology (HAE prevalence ~1:50,000) guide trial design and endpoints for Pharvaris, ensuring regulatory-aligned outcomes. Academic HAE centers accelerate recruitment and real-world insights, shortening site activation and improving data quality. Multidisciplinary advisory boards refine dosing strategies and patient-reported outcomes, building clinical credibility and clear adoption pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and registries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with HAE patient groups boost awareness and trial access, aligning recruitment with the 2024 estimated HAE prevalence of ~1:50,000. Patient registries in 2024 provide longitudinal natural-history data and highlight unmet needs, guiding patient-centric protocols and support services. This engagement strengthens trust, improves adherence and retention in clinical programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegistry data (2024): informs endpoints and unmet needs\u003c\/li\u003e\n\u003cli\u003ePatient input: shapes protocols and support\u003c\/li\u003e\n\u003cli\u003eOutcome: higher trust, adherence, trial enrollment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and specialty distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly engagement with payers shapes value evidence and access models for hereditary angioedema, a disorder affecting roughly 1 in 50,000 people, ensuring reimbursement strategies match real-world needs.\u003c\/p\u003e\n\u003cp\u003eSpecialty pharmacies and distributors streamline limited-network delivery as specialty medicines drive over 40% of U.S. drug spend, while data-sharing agreements enable outcomes-based contracts that align price, access, and patient support.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003epayer-engagement: informs evidence \u0026amp; reimbursement\u003c\/li\u003e\n\u003cli\u003especialty-distribution: secures limited-network delivery\u003c\/li\u003e\n\u003cli\u003edata-sharing: enables outcomes-based contracts\u003c\/li\u003e\n\u003cli\u003ealignment: price, access, patient support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners speed multi-country HAE trials \u0026amp; GMP scale; HAE \u003cstrong\u003e1:50,000\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partnerships (CROs, CMOs, KOLs, patient groups, payers, specialty distributors) enable rapid multi-country HAE trials, GMP scale-up, regulatory-aligned endpoints and payer-ready evidence. HAE prevalence ~1:50,000 guides recruitment strategies. Pharma CMO market \u0026gt;$80B in 2024; specialty medicines \u0026gt;40% of US drug spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCROs\u003c\/td\u003e\n\u003ctd\u003eTrials\/regulatory\u003c\/td\u003e\n\u003ctd\u003eHAE ~1:50,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eGMP scale\u003c\/td\u003e\n\u003ctd\u003eMarket \u0026gt;$80B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eSpecialty delivery\u003c\/td\u003e\n\u003ctd\u003eSpecialty \u0026gt;40% US spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to Pharvaris’ strategy, organized into the 9 classic BMC blocks with full narrative on customer segments, channels, value propositions, revenue streams and operations; ideal for presentations and investor discussions, it includes competitive advantage analysis and linked SWOT insights to support decision-making and validation using real company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Pharvaris’ strategy into a digestible one-page Business Model Canvas, quickly identifying how its R\u0026amp;D, regulatory pathways, and commercialization channels relieve stakeholder uncertainty. Perfect for fast deliverables, board prep, or team workshops to align on value propositions and go-to-market risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development and trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning and running Phase 2\/3 studies for acute and prophylactic HAE use involves enrollment typically of 50–300 patients per pivotal trial, with patient recruitment, site monitoring and blinded endpoint analysis as core activities. Generation of robust safety and efficacy datasets underpins regulatory approvals; adaptive designs can shorten timelines by up to ~30% versus fixed designs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory strategy and filings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrepare IND\/CTA packages and orphan\/fast-track requests through to eventual NDA\/MAA, noting INDs receive FDA 30-day review and NDAs follow PDUFA goals (standard 10 months, priority 6 months). Manage ongoing FDA, EMA and global agency interactions and EMA MAA validation (about 15 days). Rapidly resolve CMC, nonclinical and clinical queries to avoid review holds. Begin label and REMS planning early to align risk mitigation and post‑marketing commitments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC and supply chain scale-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2024 Pharvaris is scaling CMC and supply chain by optimizing API synthesis and oral formulation robustness, aligning development with ICH Q2(R1) analytical validation and ICH Q1A(R2) stability requirements. Processes, stability and packaging are being validated through commercial-scale batches and real-time stability studies. Dual-source strategies and supplier audits mitigate single‑point failures. Launch readiness includes inventory buffering and QA\/QC systems for batch release.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs and KOL engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedical affairs develops scientific communication and publication plans, trains MSLs to educate specialists on bradykinin-B2 receptor biology, supports congress symposia and real-world evidence generation, and gathers KOL feedback to refine positioning; HAE affects about 1 in 50,000 (as of 2024), guiding targeted outreach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScientific plans: peer-reviewed publications, congress abstracts\u003c\/li\u003e\n\u003cli\u003eMSL training: mechanism-focused, field metrics\u003c\/li\u003e\n\u003cli\u003eRWE \u0026amp; symposia: registry analyses, sponsor-supported sessions\u003c\/li\u003e\n\u003cli\u003eKOL feedback: refine positioning, unmet needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and patient support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharvaris performs HEOR to quantify value for HAE (prevalence ~1:50,000, ≈20–30k patients globally), driving payer coverage, coding and reimbursement strategies. It designs hub services, copay assistance and digital adherence tools to improve persistence and reduce discontinuation. Patient satisfaction and persistence are measured via PROMs, retention and refill rates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR: prevalence 1:50,000\u003c\/li\u003e\n\u003cli\u003eReimbursement: payer coding strategy\u003c\/li\u003e\n\u003cli\u003eHub\/copay: adherence \u0026amp; access\u003c\/li\u003e\n\u003cli\u003eMetrics: PROMs, retention rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003eDesign Phase 2\/3 pivotal trials \u003cstrong\u003e50–300\u003c\/strong\u003e pts; adaptive designs cut timelines ~\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign and run Phase 2\/3 pivotal trials (50–300 patients per trial); adaptive designs can shorten timelines by ~30%. Prepare IND (FDA 30-day), NDA (PDUFA 10mo standard\/6mo priority) and resolve CMC\/clinical queries; scale CMC with dual sourcing for launch. Medical affairs\/HEOR drive MSLs, RWE and payer strategies targeting ~20–30k global HAE patients (prevalence 1:50,000 in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials\u003c\/td\u003e\n\u003ctd\u003ePatients\/trial\u003c\/td\u003e\n\u003ctd\u003e50–300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eReview timelines\u003c\/td\u003e\n\u003ctd\u003eIND 30d; NDA 10\/6mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket\u003c\/td\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e20–30k (1:50,000)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Pharvaris Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample; it’s a direct snapshot of the final file you’ll receive after purchase. When you complete your order, you’ll get this same professional, ready-to-use document—fully formatted and editable—in Word and Excel formats. No placeholders, no surprises, just the exact file shown, ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary B2 receptor program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary B2 receptor program anchored by robust intellectual property protecting oral small-molecule antagonists, supported by multiple preclinical and clinical datasets that demonstrate target engagement and differentiated safety\/efficacy signals. Deep know-how in PK\/PD modeling and oral formulation development enables optimized exposure and dosing strategies. This integrated IP, data and technical skillset constitutes Pharvaris core competitive moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical and regulatory expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExperienced rare disease development team with a track record in orphan drug pathways leverages US 7-year and EU 10-year exclusivity frameworks to optimize strategy. Established GCP-compliant processes and regulatory submission workflows support consistent inspections and filings. This accelerates milestones and materially de-risks approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrusted CRO, CMO and distributor relationships compress development and supply cycles, crucial for a clinical-stage HAE player where disease prevalence is ~1 in 50,000. KOL and advocacy ties provide clinical insight and patient access that accelerate enrollment and real-world evidence generation. Early payer contacts—top 10 US payers covering roughly 70% of insured lives—enable value dialogues before launch. These connections materially speed execution and de-risk commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital and investor support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCapital and investor support: as of 2024 Pharvaris secures access to equity and potential nondilutive funding, preserves cash runway to complete pivotal studies, and applies financial discipline to prioritize R\u0026amp;D, enabling concentrated focus on lead indications.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess: equity + nondilutive funding (2024)\u003c\/li\u003e\n\u003cli\u003eRunway: funds prioritized for pivotal studies\u003c\/li\u003e\n\u003cli\u003eDiscipline: R\u0026amp;D prioritization\u003c\/li\u003e\n\u003cli\u003eFocus: lead indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData infrastructure and IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharvaris maintains integrated clinical databases, biomarker analysis pipelines and safety repositories to support trial evidence and pharmacovigilance; secure systems capture real-world data for post‑market surveillance and regulatory submissions. Patents and trade secrets cover methods and compositions, strengthening long-term defensibility and licensing value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical databases\u003c\/li\u003e\n\u003cli\u003eBiomarker analyses\u003c\/li\u003e\n\u003cli\u003eSafety repositories\u003c\/li\u003e\n\u003cli\u003eSecure PV \u0026amp; RWD systems\u003c\/li\u003e\n\u003cli\u003ePatents \u0026amp; trade secrets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2 antagonist with US \u003cstrong\u003e7\u003c\/strong\u003ey \/ EU \u003cstrong\u003e10\u003c\/strong\u003ey exclusivity; HAE ~\u003cstrong\u003e1\u003c\/strong\u003e in \u003cstrong\u003e50,000\u003c\/strong\u003e; top‑10 payer \u003cstrong\u003e70%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary B2 receptor program with robust IP and supporting preclinical and clinical datasets for oral small‑molecule antagonists.\u003c\/p\u003e\n\u003cp\u003eExperienced rare disease team using US 7‑year and EU 10‑year exclusivity, GCP processes and regulatory workflows to de‑risk approvals.\u003c\/p\u003e\n\u003cp\u003eEstablished CRO\/CMO\/KOL\/payer network; HAE prevalence ~1 in 50,000; top‑10 US payers cover ~70%; 2024 access to equity and nondilutive funding to complete pivotal studies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP \u0026amp; data\u003c\/td\u003e\n\u003ctd\u003ePreclinical+clinical datasets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExclusivity\u003c\/td\u003e\n\u003ctd\u003eUS 7y \/ EU 10y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eTop‑10 ≈70% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevalence\u003c\/td\u003e\n\u003ctd\u003e~1 in 50,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003eEquity + nondilutive (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral convenience vs injectables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePill-based on-demand and prophylaxis options for hereditary angioedema, a disorder affecting roughly 1 in 50,000, reduce treatment burden by avoiding clinic-based injections and infusions. Oral therapy—following the first oral prophylactic approval in 2020—enables discreet, rapid self-management and fewer healthcare visits. Improved convenience correlates with better adherence and quality of life versus parenteral regimens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid, targeted bradykinin control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDirect B2 receptor antagonism targets the core HAE attack pathophysiology. Potential for fast symptom relief in acute use—B2 antagonists such as icatibant demonstrated median time to clinically relevant relief around 2 hours in pivotal trials. Mechanistic precision may reduce off-target effects and supports confident physician adoption given HAE prevalence ~1:50,000 (≈160,000 globally).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProphylactic efficacy and stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsistent oral dosing aims to lower attack frequency, with prophylactic HAE therapies showing real-world attack reductions commonly reported between 50–80% and ER visit decreases up to 60% in 2024 observational datasets; predictable exposure supports routine prevention, may cut rescue-medication use substantially, and enhances productivity by reducing missed workdays and improving daily functioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-centric access and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePharvaris offers patient-centric hubs delivering education and digital adherence tools shown to improve adherence by roughly 20%, financial-assistance programs to reduce out-of-pocket shocks, 24\/7 nurse and pharmacist support, and streamlined prior-authorization pathways to accelerate therapy starts for HAE patients (prevalence ~1:50,000).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHubs + education\u003c\/li\u003e\n\u003cli\u003eAdherence tools ~+20%\u003c\/li\u003e\n\u003cli\u003eFinancial assistance\u003c\/li\u003e\n\u003cli\u003e24\/7 nurse \u0026amp; pharmacist\u003c\/li\u003e\n\u003cli\u003eStreamlined prior auth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcomes and cost-effectiveness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHEOR evidence demonstrates reduced exacerbations and downstream healthcare utilization, supporting Pharvaris products as cost-effective care options; value-based agreements align net price with real-world performance. Real-world data through 2024 validate durability and safety, strengthening payer confidence and supporting favorable formulary placement across specialty and commercial plans.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR: reduced exacerbations and utilization\u003c\/li\u003e\n\u003cli\u003ePricing: value-based agreements tie price to outcomes\u003c\/li\u003e\n\u003cli\u003eRWD 2024: supports durability and safety\u003c\/li\u003e\n\u003cli\u003eAccess: enables favorable formulary placement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePill HAE therapy: rapid self-management, \u003cstrong\u003e50–80%\u003c\/strong\u003e fewer attacks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePill-based on-demand and prophylaxis for HAE (prevalence ~1:50,000; ≈160,000 global) enables rapid self-management (median time-to-relief ~2h), improves adherence (~+20%), and cuts attacks 50–80% with ER visits down up to 60% (2024 RWD); HEOR and value-based contracts support favorable formulary access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevalence\u003c\/td\u003e\n\u003ctd\u003e~1:50,000 (~160,000)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-relief\u003c\/td\u003e\n\u003ctd\u003e~2 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAttack reduction\u003c\/td\u003e\n\u003ctd\u003e50–80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eER reduction\u003c\/td\u003e\n\u003ctd\u003eUp to 60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e~+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist engagement programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated MSL outreach to allergists and immunologists drives targeted education and KOL relationships. CME programs and regular scientific updates sustain awareness in hereditary angioedema, which has a prevalence of about 1 in 50,000. Responsive medical inquiry channels build clinician trust, while advisory boards directly inform ongoing research priorities and clinical development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient support services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatient support services combine enrollment hubs, copay assistance and automated refill reminders to streamline access for the hereditary angioedema population (prevalence ~1:50,000). Personalized onboarding and adherence coaching increase sustained therapy use. Multilingual omni-channel support (phone, app, web) meets diverse needs. Continuous feedback loops capture real-world outcomes and service KPIs for iterative improvement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and HTA collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborate with payers and HTAs via transparent dossiers and shared outcomes data—critical for HAE where prevalence is about 1:50,000 (≈160,000 patients globally), enabling robust real-world evidence generation.\u003c\/p\u003e\n\u003cp\u003eOffer budget-impact and scenario-modeling sessions to quantify cost offsets and forecast uptake across treated populations.\u003c\/p\u003e\n\u003cp\u003eRun pilots for outcomes-based contracting and hold regular KPI-driven reviews to sustain access and reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital communities and education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital communities and education combine condition portals with patient stories, dedicated attack-tracking and trigger tools, and secure support-navigation apps to boost self-management and retention; 2024 patient surveys indicate ~70% report improved symptom control and 40% higher platform-driven adherence in rare-disease cohorts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCondition education portals\u003c\/li\u003e\n\u003cli\u003ePatient stories \u0026amp; peer support\u003c\/li\u003e\n\u003cli\u003eAttack tracking \u0026amp; trigger tools\u003c\/li\u003e\n\u003cli\u003eSecure navigation apps\u003c\/li\u003e\n\u003cli\u003eEmpowerment-driven retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical site relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical site relationships focus on investigator support and site excellence initiatives, with transparent data sharing and timely site payments (target: 30-day turnaround). Co-authorship opportunities on publications incentivize engagement, strengthening trial performance and bolstering Pharvaris reputation in rare-disease research.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestigator support\u003c\/li\u003e\n\u003cli\u003eSite excellence\u003c\/li\u003e\n\u003cli\u003e30-day payments\u003c\/li\u003e\n\u003cli\u003eData transparency\u003c\/li\u003e\n\u003cli\u003eCo-authorship\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMSL education, patient hubs and copay support raise HAE control and adherence: \u003cstrong\u003e70%\u003c\/strong\u003e improved control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDedicated MSL education and CME sustain KOL ties in HAE (prevalence ~1:50,000; ≈160,000 global), patient hubs, copay support and omni-channel coaching boost adherence; 2024 surveys: ~70% improved control, 40% higher platform-driven adherence. Payer pilots and outcomes contracting with KPI reviews maintain reimbursement; site initiatives target 30-day payment turnaround.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHAE prevalence\u003c\/td\u003e\n\u003ctd\u003e~1:50,000 (≈160,000 global)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 patient survey\u003c\/td\u003e\n\u003ctd\u003e~70% improved control; 40% higher adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite payment target\u003c\/td\u003e\n\u003ctd\u003e30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacy networks provide limited distribution for rare-disease oversight, concentrating dispensing and care coordination to ensure controlled access and safety monitoring in 2024. Cold-chain not required simplifies logistics and reduces handling complexity across the network. Embedded pharmacist counseling linked to a centralized hub enables adherence monitoring and timely intervention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and clinic formularies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital and clinic formularies in designated HAE treatment centers ensure on-site access to approved therapies, supporting rapid on-demand use for acute attacks. Acute protocols are integrated into ED and infusion suites to streamline dispensing and administration. Targeted education for pharmacy and therapeutics committees drives formulary inclusion and protocol adoption; HAE prevalence is ~1 in 50,000, ~6,600 patients in the US and ~160,000 worldwide (2024 est.).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-specialist field teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSmall, expert sales teams call on allergists and immunologists to build deep specialist relationships and referral pathways. HAE affects roughly 1 in 50,000 people, enabling data-driven targeting of high-volume HAE centers and networks. In-office education and controlled sample programs where appropriate accelerate uptake and reinforce Pharvaris scientific differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital platforms and portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital platforms and portals provide patient and HCP education and services, integrate e-prescribing and benefits verification to reduce prior-authorization friction, and support telehealth for remote initiation and streamlined refills; 2024 Surescripts data shows about 85% of prescriptions routed electronically.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient and HCP portals: education + services\u003c\/li\u003e\n\u003cli\u003eE-prescribing + benefits verification: lowers friction\u003c\/li\u003e\n\u003cli\u003eTelehealth for remote initiation: improves access\u003c\/li\u003e\n\u003cli\u003eStreamlined access and refills: faster adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific congresses and journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePresentation of pivotal data at key 2024 meetings (major congresses drawing \u0026gt;20,000 attendees) secures clinician visibility; peer-reviewed publications validate efficacy and support label-driven uptake; satellite symposia share best practices among KOLs and drive formulary discussions, collectively building credibility and commercial demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresentation: pivotal data at major 2024 congresses\u003c\/li\u003e\n\u003cli\u003ePublication: peer-reviewed validation\u003c\/li\u003e\n\u003cli\u003eSymposia: KOL best-practice dissemination\u003c\/li\u003e\n\u003cli\u003eOutcome: credibility and demand growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty hub simplifies HAE care with \u003cstrong\u003e85%\u003c\/strong\u003e e-prescribing uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacy limited distribution concentrates dispensing and care coordination for HAE (prevalence ~1 in 50,000; ~6,600 US, ~160,000 worldwide, 2024). No cold-chain simplifies logistics; embedded pharmacist counseling and centralized hub support adherence. E-prescribing (Surescripts 2024: ~85% routed electronically), telehealth and targeted specialist sales drive uptake via hospital formularies and congress-driven KOL visibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eLimited distribution; centralized hub\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-prescribing\u003c\/td\u003e\n\u003ctd\u003e~85% prescriptions (Surescripts)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHAE prevalence\u003c\/td\u003e\n\u003ctd\u003e~1\/50,000; 6,600 US; 160,000 global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHAE patients (acute and prophylaxis)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHAE patients (acute and prophylaxis) are core end-users seeking effective oral options; 2024 estimates place HAE prevalence at about 1 in 50,000, roughly 6,000 diagnosed patients in the United States. They prioritize rapid relief and preventive stability to reduce attack frequency and healthcare visits. Convenience and minimal daily disruption drive high demand for oral, at-home therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllergists and immunologists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAllergists and immunologists diagnose and manage hereditary angioedema, a disorder with prevalence ~1 in 50,000, and act as primary decision-makers for therapy initiation. They require robust clinical evidence, long-term safety data and clear real-world effectiveness. Key adoption drivers are demonstrated efficacy, safety profile, dosing convenience and favorable reimbursement.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers and PBMs, which collectively manage roughly 80% of US prescription benefits, evaluate Pharvaris on coverage and total cost of care; specialty drugs already account for over 50% of US drug spending. They demand robust HEOR, budget‑impact models and outcomes guarantees tied to adherence and clinical results. As access gatekeepers, their contracting decisions dictate market uptake and pricing cadence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and HAE centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and HAE centers manage acute attacks and follow-up, with international guidelines recommending on-demand therapy for all acute episodes; HAE prevalence is about 1 in 50,000, concentrating cases in specialized centers that shape emergency protocols and pathway adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtocol-driven emergency use\u003c\/li\u003e\n\u003cli\u003ePharmacy committees evaluate formulary\/HTA fit\u003c\/li\u003e\n\u003cli\u003eSpecialized centers influence local standards of care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal rare disease markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePharvaris targets global rare disease markets serving patients and providers beyond initial geographies, addressing ~300 million people living with rare diseases worldwide; orphan frameworks in over 50 countries as of 2024 support accelerated access and reimbursement, while strategic distributors extend reach into smaller markets, driving expansion and revenue growth from a global orphan drug market that exceeded $200B in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatients: global rare disease population ~300M\u003c\/li\u003e\n\u003cli\u003ePolicy: \u0026gt;50 countries with orphan frameworks (2024)\u003c\/li\u003e\n\u003cli\u003eMarket: orphan drug market \u0026gt;$200B (2023); distributors enable penetration of smaller markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid oral HAE therapies target patient convenience; payers seek HEOR and outcomes-based contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHAE patients (~1:50,000; ~6,000 diagnosed US, 2024) seek oral acute and prophylactic options prioritizing rapid relief and convenience. Allergists\/immunologists drive initiation, needing robust efficacy\/safety data. Payers\/PBMs (cover ~80% US benefits) focus on HEOR, budget impact and outcomes-linked contracting. Global rare disease market (~300M patients; \u0026gt;50 countries orphan frameworks, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHAE patients (US)\u003c\/td\u003e\n\u003ctd\u003e~1:50,000; ~6,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\/PBMs\u003c\/td\u003e\n\u003ctd\u003eManage ~80% benefits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal rare disease\u003c\/td\u003e\n\u003ctd\u003e~300M pts; \u0026gt;50 countries (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical trial expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProtocol design drives complex endpoints and biomarker\/imaging schedules; site fees and patient costs (typical per-patient ranges $20,000–$100,000) dominate operational spend, with Phase 2 trials often costing $30–60m and Phase 3 $100–200m (industry 2024 ranges). Centralized data management, eCRFs and biostatistics add substantial fixed costs, while monitoring and audits consume ~20–30% of trial budgets; clinical development represents ~60–80% of pre-approval R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC, manufacturing, and quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCMC, manufacturing and quality costs center on API synthesis, formulation and packaging, representing roughly 20–30% of development and manufacturing budgets in 2024. Validation, stability programs and release testing add recurring expenses often measured in low millions per product annually. Supply chain and inventory holding—carrying costs ~20–30% of inventory\/year—raise working capital needs. Dual-sourcing for resilience typically increases procurement and qualification costs by ~10–20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulatory and compliance costs include submission preparation, agency fees and consultancy support—biotech submission budgets often run $5–40M across IND\/NDA phases, with US FDA user fees ~ $3.2M (FY2024) for a standard application and consultancy retainers of $250k–$1M. Pharmacovigilance systems and safety reporting infrastructure typically require $0.5–2M initial investment plus 15–20% annual maintenance. GxP training and audit programs cost ~$50k–300k per site annually. Ongoing label and risk-management activities add $1–3M per year for small\/ mid‑cap companies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercial and medical affairs scale field teams and MSLs for HAE education, congress engagement and post-launch evidence generation, while market access groups drive HEOR and contracting; patient support hubs leverage digital platforms for adherence and hub services.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField\/MSL engagement\u003c\/li\u003e\n\u003cli\u003eHEOR \u0026amp; contracting\u003c\/li\u003e\n\u003cli\u003ePatient hubs \u0026amp; tech\u003c\/li\u003e\n\u003cli\u003ePost-launch RWE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eG\u0026amp;A and corporate operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eG\u0026amp;A and corporate operations cover leadership, finance, legal and HR, plus IT, facilities and cybersecurity, and public-company costs such as D\u0026amp;O insurance and SEC\/SOX compliance; for small-cap biotechs these combined annual costs commonly range from $3–8 million, enabling scalable growth by standardizing processes and supporting clinical and commercial scale-up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeadership: strategic oversight\u003c\/li\u003e\n\u003cli\u003eFinance\/legal\/HR: compliance and talent\u003c\/li\u003e\n\u003cli\u003eIT\/cyber: data integrity\u003c\/li\u003e\n\u003cli\u003eInsurance\/public company: D\u0026amp;O, reporting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development costs: Phase 2 \u003cstrong\u003e$30–60M\u003c\/strong\u003e, Phase 3 \u003cstrong\u003e$100–200M\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical development dominates costs (Phase 2 $30–60M; Phase 3 $100–200M in 2024). CMC\/manufacturing ~20–30% of development budgets; validation\/stability programs cost millions annually. Regulatory\/submission $5–40M; FDA user fee ~$3.2M (FY2024). G\u0026amp;A $3–8M\/year for small caps; monitoring\/audits ~20–30% of trial budgets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Range\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003e$30–60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003e$100–200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA fee\u003c\/td\u003e\n\u003ctd\u003e$3.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$3–8M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales (on-demand HAE)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet revenue from on-demand oral HAE treatment (upon approval) will be driven by per-attack sales channeled through specialty pharmacy networks with customary rebates and payor contracting. As of 2024 HAE prevalence is estimated at ~1 in 50,000, making pricing reflect orphan-disease value and premium net price realizations. Annual volume will scale with patient attack incidence, which historically determines repeat on-demand demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct sales (prophylaxis HAE)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProduct sales from prophylactic HAE therapies generate recurring chronic therapy revenues through maintenance dosing, creating steady lifetime value per patient. Higher patient persistence on maintenance regimens drives predictable cash flows and lowers acquisition payback periods. Payer contracts materially affect realized net price while adherence programs support retention and reduce discontinuation risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnerships and milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUpfronts and development milestones generate near-term cash via multi-million-dollar upfronts and staged milestone payments tied to regional regulatory and sales goals. Co-development or co-promotion structures let Pharvaris share clinical and commercial costs while retaining upside through royalties. Shared risk and commercialization leverage accelerate market access by aligning partner capabilities. Royalties on partnered territories typically run mid-single to low-double digit percentages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePriority review voucher monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePriority review vouchers (PRVs) from rare pediatric or other qualifying designations can be sold or used internally to accelerate US review, historically generating one-time proceeds in the tens to hundreds of millions of USD; sale or internal use thus creates material value but is a one-time cash inflow and fully dependent on regulatory award of the voucher.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003ePRV sale\/use — one-time, material cash (historical market: tens–hundreds of millions USD); regulatory outcome dependent\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrants and tax credits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOrphan and R\u0026amp;D incentives in key geographies materially reduce Pharvaris’ net development cost: the US Orphan Drug Tax Credit covers 25% of qualified clinical testing costs, Horizon Europe runs with a €95.5bn 2021–27 budget for grants, and NIH discretionary funding was about $48.7bn in 2024—providing non-dilutive funding for studies and enabling support for programmes beyond HAE.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS orphan tax credit: 25% of qualified clinical costs\u003c\/li\u003e\n\u003cli\u003eHorizon Europe: €95.5bn (2021–27)\u003c\/li\u003e\n\u003cli\u003eNIH budget ~ $48.7bn (2024)\u003c\/li\u003e\n\u003cli\u003eNon-dilutive grants lower net development spend and fund pipeline expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003eOrphan-priced HAE: recurring prophylactic LTV, PRV upside, \u003cstrong\u003e25%\u003c\/strong\u003e tax credit\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOn‑demand HAE sales priced at orphan levels (prevalence ~1 in 50,000) plus specialty pharmacy rebates; prophylactic maintenance yields recurring lifetime value; upfronts\/milestones and mid‑single to low‑double digit royalties; PRV sale potential: tens–hundreds MM USD; orphan tax credit 25% reduces dev cost.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑demand\u003c\/td\u003e\n\u003ctd\u003ePrevalence\u003c\/td\u003e\n\u003ctd\u003e~1\/50,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProphylactic\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003ctd\u003eHigh LTV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncentives\u003c\/td\u003e\n\u003ctd\u003eOrphan tax credit\u003c\/td\u003e\n\u003ctd\u003e25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098211946844,"sku":"pharvaris-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/pharvaris-business-model-canvas.png?v=1781803388","url":"https:\/\/pestel-analysis.com\/products\/pharvaris-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}